Decentralized Clinical Trials (DCTs) have become a standard operational model in France by late 2025, reflecting a move toward more patient-centric research designs that reduce the burden of travel to central hospitals. This hybrid approach utilizes telemedicine, mobile nursing units, and wearable sensors to collect high-quality clinical data directly from the patient’s home. For the research sector, this transition requires a robust technological infrastructure and clear protocols for ensuring data integrity in non-traditional settings. According to the France Contract Research Organization Sector, DCTs are particularly effective for long-term observational studies and trials involving patients with mobility challenges or those living in rural areas. This flexibility not only boosts patient retention but also ensures a more diverse and representative participant pool, which is vital for the generalizability of trial results.

Frequently Asked Questions

Q. What is eConsent in a decentralized trial? A. It is a digital process that uses videos and interactive tools to ensure a patient fully understands the trial before providing their consent electronically.

Q. Are fully decentralized trials common in France? A. Most trials in 2025 follow a "hybrid" model, combining some remote elements with essential in-person visits to clinical sites for complex procedures.